In our study, immunoreactivity of Glut-1 was detected in 100% of the melanocytic nevi, in 75% of the Spitz nevi and in 45% of the melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant. Here, SLC2A3 is linked to melanoma.